What smart money is saying about AbbVie
2 funds in our archive have pitched AbbVie — most recently Augustine Asset Management Quarterly Fund in September 2026.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Get an email when a fund buys, sells or pitches it
Position history
Between Q1 2025 and Q3 2026, 13 fund letters reported a position in AbbVie — 1 opened or added to the position, 3 trimmed or exited.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 4 | 1 | 0 | 1 |
| Q2 2026 | 7 | 0 | 2 | 0 |
| Q3 2025 | 0 | 0 | 0 | 1 |
| Q2 2025 | 1 | 0 | 0 | 0 |
| Q1 2025 | 1 | 0 | 1 | 0 |
Fund activity · 13 positions · 4 moves
- HoldsHamlin Capital Management Equity and High Yield Municipal Bond StrategiesSeptember 2026
“ConocoPhillips, CME, and AbbVie led the portfolio in the third quarter, gaining 15.02% on average.”
AbbVie - September 2026
Listed in Harding Loevner Global Equity’s reported holdings.
AbbVie - New positionAugustine Asset Management Quarterly FundSeptember 2026
“During the quarter, we initiated a new position in AbbVie, a US biopharmaceutical company with leadership positions in immunology, neuroscience, oncology and aesthetics.”
AbbVie - September 2026
Listed in Harding Loevner Global Developed Markets Equity’s reported holdings.
AbbVie - TrimmedDistillate CapitalJune 2026
“AbbVie, Inc. 2.0% 3.2%”
AbbVie - June 2026
Listed in Harding Loevner Global Equity’s reported holdings.
AbbVie - June 2026
Listed in Guinness Global Equity Income Fund’s reported holdings.
AbbVie - June 2026
“Portfolio Highlights The ClearBridge Appreciation Strategy underperformed the benchmark S&P 500 Index in the second quarter of 2026. On an absolute basis, the Strategy had positive contributions from eight of 11 sectors. The IT sector was the main positive contributor, while energy was the main detractor. In relative terms, stock selection and sector allocation detracted. Stock selection in IT, industrials, communication services, financials and consumer discretionary, overweights to materials and energy and an IT underweight detracted the most. Conversely, stock selection in materials and a consumer discretionary underweight were beneficial. On an individual stock basis, the biggest relative contributors during the quarter were ASML, Palo Alto Networks, ASM International, an underweight to Microsoft and not owning Palantir. The biggest detractors were Netflix, underweights to Micron Technology and Advanced Micro Devices, and not owning Intel and Applied Materials. During the quarter, we initiated new positions in SpaceX in communication services, Micron Technology, Cisco Systems, Advanced Micro Devices and Texas Instruments in IT and Diamondback Energy in energy. We exited Roblox in communication services, Boston Scientific and AbbVie in health care and Solstice Advanced Materials in materials.”
AbbVie - June 2026
“Top 10 holdings Weighting (%) Alphabet Inc. Class A 6.43 Apple Inc. 3.55 Micron Technology, Inc. 3.08 Microsoft Corporation 2.87 Taiwan Semiconductor Manufacturing Co., Ltd. Sponsored ADR 2.85 JPMorgan Chase & Co. 2.30 Cisco Systems, Inc. 2.15 AbbVie, Inc. 2.10”
AbbVie - HoldsHomestead Advisers FundsJune 2026
Listed in Homestead Advisers Funds’s reported holdings.
AbbVie - HoldsHomestead Advisers Value FundJune 2026
Listed in Homestead Advisers Value Fund’s reported holdings.
AbbVie - HoldsEpoch Global Equity Shareholder YieldJune 2025
“Among the largest detractors were AbbVie and Bristol-Myers Squibb.”
AbbVie - March 2025
“We closed out of AbbVie, in the health care sector, a biopharmaceutical company developing treatments for autoimmune diseases and cancer.”
AbbVie
Also mentioned · 1
These funds discuss AbbVie — as a competitor, benchmark or comparable — without disclosing a position in it.
- MentionedBaron Health Care FundJune 2026
“Favorable stock selection in biotechnology, mostly attributable to acquisition target Apogee Therapeutics, Inc. , was partly offset by higher exposure to this underperforming sub-industry. In June, Apogee announced an agreement to be acquired by AbbVie Inc. for $135.11 per share, representing a 49.5% premium over the prior day’s closing stock price.”
AbbVie
Fund coverage · 2 theses
- Augustine Asset Management Quarterly FundSeptember 2026
AbbVie has leadership franchises and a post-Humira growth platform supported by high and improving returns on capital, a strong pipeline, and an attractive valuation.
Read the full thesis - Baron Health Care FundSeptember 2025
AbbVie Inc. is a large biopharmaceutical company poised for sustained growth due to strong product offerings and no major patent expirations until the mid-2030s.
Read the full thesis
Read every full thesis on AbbVie
Unlock all 2 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→